September 2021 Issue - Endovascular Today

Table of Contents

Issue

September 2021

SFA Challenges and Progress

In This Issue

Guest Chief Medical Editors' Page

Femoropopliteal Disease: Challenges and Progress

By Marianne Brodmann, MD, and Ehrin J. Armstrong, MD, MSc, MAS, FACC, FSCAI, FSVM

Cover Stories

A Safety Update on Paclitaxel-Coated Devices for Peripheral Vascular Intervention

An overview of the controversy surrounding a late mortality signal associated with paclitaxel-coated devices and an exploration of new data regarding their safety.

By Anna Krawisz, MD, and Eric A. Secemsky, MD, MSc

United States Regulatory Perspectives on Paclitaxel in PAD

Moderator Dr. Gary Ansel asks representatives from the FDA’s Center for Devices and Radiological Health about controlling for ascertainment and investigator bias in future vascular device trials, potential changes for drug-based device approvals, how the agency weighs the level of data required for approval of new vascular devices, the statistical strength of the data from general use studies, and the level of data needed to update FDA’s position on paclitaxel-containing devices.

With Eleni Whatley, PhD; Misti Malone, PhD; Sara Royce, PhD; and Kenneth Cavanaugh, PhD

The Near Future of Antiproliferative Therapy for Femoropopliteal Disease

Discussing the methods of vascular drug delivery in the treatment of SFA lesions.

By Sahil A. Parikh, MD, and Navneet Sharma, MD

Challenges and Opportunities in the Treatment of Vascular Calcification in Peripheral Artery Disease

Disease pathology and epidemiology, diagnosis and classification, treatment options, and novel treatments.

By Yousif Al-Saiegh, MD, and William A. Gray, MD

Panel Discussion: Endovascular Therapies for TASC C and D Femoropopliteal Disease

Prof. Ramon L. Varcoe asks Drs. Herbert D. Aronow, Darren B. Schneider, and Sabine Steiner about current evidence for treatment of TASC C and D lesions, their preferred access and approach to advanced disease, if lesion location affects decision-making, and which new therapies hold promise for treating these complex lesions.

Panel Discussion: CFA Disease: Exploring Options in a Typically Surgical Indication

Moderator Peter A. Schneider, MD, asks Daniela Branzan, MD; Daniel Clair, MD; Tony Das, MD, FACC; and Yann Gouëffic, MD, PhD, about their approaches to CFA lesions, patient and clinical factors they consider, data that support an endovascular approach, preferred tools and rules of thumb, and how treatment of CFA disease looks in the future.

Featured Technology

In This Issue

Most Read Articles